LONDON, October 20, 2014 /PRNewswire/ --
Richmond Pharmacology has extended its capacity with an additional six-bed facility dedicated to screening and out-patient procedures for early phase studies in patients, complementing its existing 68-bed facility within Croydon University Hospital.
The new facility is adaptable to accommodate the requirements of different patient populations and study procedures.
Richmond Pharmacology also recently re-configured one of its clinical wards to accommodate patients with mental health conditions for studies requiring long-term in-house stays; creating a safe and research-focused environment, which at the same time is perceived very positively by the patients.
Richmond Pharmacology's longstanding track record to include patients into early phase trials is well known for its accurate recruitment predictions and fast patient recruitment.
Dr Keith Berelowitz, the Director of Operations commented: "It is the combination of medical expertise, an extensive patient database and a sleek, professional clinical trials unit that makes this a model for how clinical trials should be run."
Richmond Pharmacology's bespoke database of more than 185,000 people registered and willing to participate in a clinical trial is a major factor contributing to the company's ability to conduct unusual and challenging early patient studies. Through extensive experience in conducting pre-study feasibility assessments with the target population, Richmond Pharmacology provides Sponsors with invaluable insight into incidence, study acceptability and suitability of "study" populations. This helps shape protocol development to adhere to study timeline and budget requirements.
Dr Lorch, Medical Director, commented: "An experienced team of clinical pharmacologists and operational specialists assess each patient study for its feasibility and requirements prior to the company committing to a trial. This has earned us our good reputation for being reliable trial specialists." Current studies include patients with osteoarthritis, cosmetic indications, diabetes and orphan diseases.
Benefit from fast and efficient recruitment; contact Richmond Pharmacology with your requirements.
Dr Jorg Taubel, Chief Executive Officer, +44(0)-208-664-5200, email@example.com
SOURCE Richmond Pharmacology Limited